Picture of RegeneRx Biopharmaceuticals logo

RGRX RegeneRx Biopharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapValue Trap

Momentum

Relative Strength (%)
1m-2.64%
3m+11.34%
6m-99.94%
1yr-99.99%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-1775.74%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of RegeneRx Biopharmaceuticals EPS forecast chart

Profile Summary

RegeneRx Biopharmaceuticals, Inc. (RegeneRx) is a biopharmaceutical company. The RegeneRx is focused on the development of a therapeutic peptide Thymosin beta 4(Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptid originally isolated from bovine thymus glands. The Company's product candidates in clinical development includes RGN-259, RGN-352, and RGN-137. The Company's RGN -259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases. Its RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

Directors

Last Annual
December 31st, 2022
Last Interim
March 31st, 2023
Incorporated
May 13th, 1982
Public Since
December 23rd, 1986
No. of Employees
2
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
1,496,966

RGRX Share Price Performance

Upcoming Events for RGRX

Similar to RGRX

Picture of Acacia Diversified Holdings logo

Acacia Diversified Holdings

us flag iconPink Sheets on Nasdaq

Picture of Acusphere logo

Acusphere

us flag iconPink Sheets on Nasdaq

Picture of Adorbs logo

Adorbs

us flag iconPink Sheets on Nasdaq

Picture of Agentix logo

Agentix

us flag iconPink Sheets on Nasdaq

Picture of Agrios Global Holdings logo

Agrios Global Holdings

us flag iconPink Sheets on Nasdaq

FAQ